Trial · NCT02101385
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Two-Year Disease-Free Survival (DFS) | Arm A (Genomically Directed Monotherapy) | 56.6 | percentage of participants | ||
| Percentage of Participants With Two-Year Disease-Free Survival (DFS) | Control Arm B (Observation/Standard Therapy) | 62.4 | percentage of participants | ||
| Comparison Between Overall Disease-Free Survival | Arm A (Genomically Directed Monotherapy) | NA | 95% Confidence Interval 16.6 to NA | months | |
| Comparison Between Overall Disease-Free Survival | Control Arm B (Observation/Standard Therapy) | 48.7 | 95% Confidence Interval 20.8 to NA | months | |
| Comparison Between One Year Disease Free Survival | Arm A (Genomically Directed Monotherapy) | 63.5 | percentage of participants | ||
| Comparison Between One Year Disease Free Survival | Control Arm B (Observation/Standard Therapy) | 72.7 | percentage of participants | ||
| Five-Year Overall Survival (OS) Rate | Arm A (Genomically Directed Monotherapy) | 0.52 | probability | ||
| Five-Year Overall Survival (OS) Rate | Control Arm B (Observation/Standard Therapy) | 0.62 | probability | ||
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | Arm A (Genomically Directed Monotherapy) | Number of patients had at least one adverse event of any grade | 65 | Participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | Control Arm B (Observation/Standard Therapy) | Number of patients had at least one adverse event of any grade | 34 | Participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | Arm A (Genomically Directed Monotherapy) | Number of patients had at least one grade 3 or greater adverse event | 23 | Participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | Control Arm B (Observation/Standard Therapy) | Number of patients had at least one grade 3 or greater adverse event | 10 | Participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | Arm A (Genomically Directed Monotherapy) | Number of patients had at least one grade 3 or greater treatment related adverse event | 23 | Participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | Control Arm B (Observation/Standard Therapy) | Number of patients had at least one grade 3 or greater treatment related adverse event | 10 | Participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | Arm A (Genomically Directed Monotherapy) | Number of patients having serious adverse event | 2 | Participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | Control Arm B (Observation/Standard Therapy) | Number of patients having serious adverse event | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02101385/results